Effects of Tomato-Soy Juice on Biomarkers in Patients With Prostate Cancer Undergoing Prostatectomy

OBJECTIVES:

Primary

- Determine the incidence and severity of toxicity associated with tomato-soy juice in
patients undergoing prostatectomy.

Secondary

- Quantify changes in the content and distribution of soy isoflavones and tomato
phytochemicals (carotenoids and polyphenols) to the prostate and correlate tissue
content and patterns with blood and urinary concentrations of these compounds and their
metabolites.

- Determine blood hormonal patterns and biomarkers of oxidative stress that favor
prostate cancer prevention.

- Investigate histopathologic and molecular biomarkers associated with prostate
carcinogenesis that may serve as surrogate endpoint biomarkers and provide information
regarding their ability to be modulated by the tomato-soy juice.

- Examine several critical histopathologic endpoints, including systemic hormones,
cell/matrix interactions in the tumor microenvironment, and molecular processes within
the tumor cells (tumor grade and nuclear morphometry, tumor stage, proliferation index,
apoptotic index, and angiogenesis/vascularity).

- Determine if consumption of tomato-soy juice alters molecular markers in the human
prostate, including neuroendocrine markers such as IGF-I and IGF-BP3, signal
transduction markers such as PTEN (phosphatase and tensin homologue) and phospho-AKT,
and angiogenesis regulators such as VEGF (vascular epithelial growth factor).

OUTLINE: Patients receive tomato-soy juice daily for 4 weeks. Patients then undergo
prostatectomy.

Patients complete urologic symptom and quality-of-life questionnaires.

Blood, urine, and tissue samples are collected for biomarker and pharmacokinetic analysis.

DISEASE CHARACTERISTICS:

- Biopsy-proven carcinoma of the prostate

- Has chosen to undergo a radical prostatectomy (or cystoprostatectomy) for treatment
of disease after the medical team has presented all possible treatment options

PATIENT CHARACTERISTICS:

- ECOG performance status 0-1

- BUN/creatinine, liver enzymes, complete blood count, and PT/PTT/INR normal

- Agrees to have prostate biopsy blocks provided to the study for evaluation

- Agrees to consume a standardized vitamin and mineral supplement and avoid other
nutritional, dietary, or alternative medications/supplements for the duration of the
study

- No other active malignancy that requires therapy

- No history of pituitary hormone diseases that currently require supplemental hormonal
administration (thyroid hormones, ACTH, growth hormone) or other endocrine disorders
requiring hormone administration (except for diabetes or osteoporosis)

- No medical conditions, including malabsorptive disorders or other metabolic disorders
requiring special dietary recommendations, severe constipation, recent history of
anemia or iron deficiency, or hypertension that requires a strict low-sodium diet

- No known allergy to soy or tomato components

PRIOR CONCURRENT THERAPY:

- No prior traumatic or surgical castration

- No concurrent neoadjuvant hormonal therapy or chemotherapy (other clinical trials)

- No other concurrent lycopene, soy dietary supplements, or "alternative" products
(i.e., PC-SPES, or Saw Palmetto)

- No concurrent finasteride (Proscar) or other hormonal agents for
chemoprevention/treatment of benign prostate hyperplasia

- No concurrent prescription medications for urinary outlet obstructive symptoms

- No concurrent non-prescription substances to improve urinary tract symptoms (i.e.,
Saw Palmetto or other herbal or alternative products)